NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and Abivax

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced today the appointment of Dr. Keith M. Fournier, PhD, RAC, to its Board of Directors.

Dr. Fournier is a highly experienced pharmaceutical executive with more than two decades of leadership across drug development, global regulatory strategy and cross-functional portfolio management. His career has spanned the development lifecycle from Investigational New Drug (IND) activities through global registration and lifecycle management, with senior positions at several of the world’s leading pharmaceutical organizations.

Dr. Fournier currently serves as Senior Vice President, Head of Regulatory Affairs, at Abivax where he leads the company’s regulatory organization and strategy supporting advancement of its pipeline. Prior to Abivax, he served as Vice President, Global Regulatory Affairs at EMD Serono, the healthcare business of Merck KGaA, where he led approximately 75 regulatory leaders and project managers responsible for regulatory strategies across a broad global portfolio. Dr. Fournier also contributed to overall global regulatory organizational strategy as a member of the Regulatory, Quality and Safety leadership team.

In addition, Dr. Fournier previously held a series of senior leadership positions at AbbVie. As an Asset Strategy Leader within AbbVie’s oncology organization, he led cross-functional strategy for VENCLEXTA® (venetoclax) programs across hematologic and solid tumors. He previously served as Senior Director and Therapeutic Area Lead for Global Regulatory Affairs in Immunology and as Global Regulatory Lead for HUMIRA®.

Prior thereto, Dr. Fournier also spent five years at MedImmune, an AstraZeneca company, where he served as a Global Regulatory Lead across the respiratory, inflammation and autoimmune portfolio, including late-stage development programs in systemic lupus erythematosus, scleroderma and myositis.

“Keith brings the type of pharmaceutical industry experience that we believe can add significant value to NetraMark as we continue expanding our relationships with drug developers,” said George Achilleos, CEO of NetraMark. “He has spent more than 20 years inside some of the world’s most sophisticated pharmaceutical organizations making decisions around regulatory strategy, clinical development and the advancement of important therapeutic assets. His understanding of how pharmaceutical companies evaluate clinical evidence, make development decisions and interact with regulators provides an extremely valuable perspective for our Board.” Achilleos continued, “As NetraMark works with pharmaceutical and biotechnology companies to seek to extract greater value from clinical trial data and inform subsequent clinical development strategies, we believe it is increasingly important that our Board combines expertise in artificial intelligence with executives who deeply understand how drugs actually move through the development and regulatory process. Keith significantly strengthens that capability.”

Dr. Fournier commented, “Clinical development continues to face a fundamental challenge in understanding heterogeneous patient populations and identifying the factors that influence treatment response. NetraMark is approaching this problem with a differentiated technology designed specifically around the realities of clinical trial data. I am excited to join the Board and contribute my experience in drug development and regulatory strategy as the Company works to expand the application of NetraAI across the pharmaceutical industry.”

Dr. Fournier earned his PhD in Pharmacology from the University of Pennsylvania School of Medicine and holds a Bachelor of Science in Biology and Bachelor of Arts in Economics, cum laude, from Duke University. He has also authored multiple peer-reviewed scientific publications.

For more information on NetraMark and NetraAI, visit www.netramark.com.

About NetraAI

NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting," which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark

NetraMark is focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are targeted at the biotechnology and pharmaceutical industries. The Company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets often prevalent in clinical trials, and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential impact and perspective that Dr. Fournier can bring to the Company's business and ability to engage with target markets, the Company’s anticipated business plans and strategies, and the potential for our technology to extract greater value from clinical trial data and inform subsequent clinical development strategies along with the potential expansion of the application of NetraAI across the pharmaceutical industry, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.com including our Annual Information Form for the year ended September 30, 2025. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:

Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
Adam Peeler – Investor Relations | adam.peeler@loderockadvisors.com | 416-427-1235

Media Contact:
netramark@ampublicrelations.com